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Summary Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive eithercyclophosphamide, vincristine,
doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF
administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a
significant improvement in survival (P= 0.004).
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Although substantial advances in the treatment of extensive-stage
small-cell lung cancer (SCLC) have improved palliative manage-
ment, survival with a present therapeutic approach has plateaued
at 8-9 months (Aisner, 1996). The importance of dose intensity
of chemotherapy in achieving maximal therapeutic effect has
been reported for a variety of chemosensitive tumours (Frei and
Canellos, 1980). These chemotherapy studies have shown an
encouragingly high response rate. However, myelosuppression
and leucopenic fever have been major problems in these aggres-
sive therapies (Sculier et al, 1990; Taylor et al, 1990; Miles et al,
1991; Wampler et al, 1992; Alba et al, 1992). With the advent of
recombinant human granulocyte colony-stimulating factor (rhG-
CSF), it has become possible to reduce neutropenic complications
in the treatment of SCLC (Bronchud et al, 1987; Crawford et al,
1991; Trillet-Lenoir et al, 1993). Thus, the use of rhG-CSF may
allow higher dose intensities ofdrugs without incurring significant
neutropenia. This randomized trial was carried out to evaluate the
impact of rhG-CSF on dose intensity (the primary end point).
Additional end points were response rates, duration of response,
toxicity and survival in patients with extensive-stage SCLC.
PATIENTS AND METHODS
Between May 1989 and September 1991, 63 consecutive eligible
patients with extensive-stage SCLC were treated at the Osaka Pre-
fectural Habikino Hospital and the National Kinki Central Hospital.
The criteria for entry included histological or cytological proof
ofSCLC, extensive-stage disease including ipsilateral pleural effu-
sion, measurable disease or evaluable disease, no prior therapy, life
expectancy of2 8 weeks, performance status of0-2 (ECOG scale),
age of 18-75 years, adequate bone marrow reserve, normal hepatic
and renal functions, no active concomitant malignant disease and
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the written informed consent of the patient. Clinical features at
diagnosis, staging procedures and the criteria used to assess the
response to treatment have been described elsewhere (Masuda et al,
1992; Fukuokaet al, 1994). The CODE combination chemotherapy
method was very similar to the one previously described by Murray
et al (199la). In brief, the regimen consisted ofcisplatin 25 mg m-2
weekly for 9 weeks, vincristine 1 mg m-2 during weeks 1, 2, 4, 6
and 8, and doxorubicin 40 mg m-2 and etoposide 80 mg m-2 for
3 days during weeks 1, 3, 5, 7 and 9. Patients were randomly
assigned to receive the CODE regimen with or without rhG-CSF
(Kirin Brewery, Tokyo, Japan). rhG-CSF (50gg m-2) was given by
daily subcutaneous injection, except on the days of treatment.
Treatment was delayed for one week or more if total leukocyte
counts were less than I x 109 1-1 or ifplatelet counts were less than
30 x 109 1-' and then restarted with a full dose.
Thirty-two patients were treated with CODE with rhG-CSF and
31 with CODE without rhG-CSF (Table 1). The two groups were
well matched with respect to the main clinical characteristics
except for sex.
Patients were followed up regularly in the outpatient clinic for
signs of relapse, toxicity and intercurrent illness. None of them
were lost to follow-up.
Table 1 Patient characteristics
With rhG-CSF Without rhG-CSF P-value
No. of patients 32 31
Age (years)
Median (range) 61 (44-73) 61 (42-73) NS
Gender
Male 25 30 0.023
Female 7 1
ECOG performance status
0,1 19 14 0.381
2 13 17
NS, not significant.
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Table 2 Actually delivered vs projected dose-intensity of individual drugs
Delivered DVprojected Dl
Drugs With rhG-CSF Without rhG-CSF P-value
Cisplatin 0.84 0.20a 0.71 ± 0.23 0.02
Vincristine 0.85 0.18 0.77 ± 0.19 0.06
Doxorubicin 0.83 ± 0.20 0.73 ± 0.22 0.04
Etoposide 0.83 ± 0.20 0.69 + 0.28 0.02
Total 0.84 ± 0.19 0.72 ± 0.22 0.03
aMean + s. d. DI, dose intensity (mg m-2 week-')
Table 3 Summary of results
With rhG-CSF Without rhG-CSF
Response
Complete response 11 7
Partial response 20 19
Overall response 31 (97%) 26 (84%)
Outcome
Alive, free of disease 0 1
Alive with disease 2 0
Dead because of disease 24 21
Treatment-related death 4 4
Sepsis 3 3
Radiation pneumonitis 1 0
Pyothorax 0 1
Dead of unrelated causes 2 5
Heart failure 1 3
Pneumonitis induced by CPT-11a 1 0
Unknown 0 2
aAt salvage therapy.
Table 4 Proportional hazards analysis for survival
Prognostic factor Hazard ratio 95% Confidence interval P-value
rhG-CSF
Without vs with 1.900 1.080-3.344 0.026
Performance status
2 vsO, 1 1.471 0.874-2.478 0.146
Liver metastasis
Yes vsno 1.417 0.791-2.541 0.242
LDHa
Increased vsnormal 1.325 0.771-2.275 0.308
aLactate dehydrogenase.
Survival curves were calculated using the method ofKaplan and
Meier (Kaplan and Meier, 1958) and compared using the log-rank
test (Peto et al, 1977). The two groups were tested for differences
in clinical attributes in 63 patients using the chi-square test or
Fisher's exact test. The Statistical Application System (SAS,
1986) was used for multivariate analysis ofprognostic variables in
survival by use of a Cox proportional hazards model (Cox, 1972).
The size of the sample was calculated with a statistical power of
80% and a significance level of 5%, on the basis of an expected
difference of 10% in the percentage of the dose intensity actually
delivered versus scheduled dose intensity (70% in the control
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Figure 1 Response duration in patients with extensive-stage small-cell lung
cancer by treatment group. The median durations of response were 33
weeks in the rhG-CSF group (-) and 22 weeks in the control group (----)
(P= 0.0546)
RESULTS
In the rhG-CSF group, 16% of patients did not complete the
intended programme, compared with 32% in the control group (P
= 0.2099). A summary ofthe received protocol treatment is listed
in Table 2. Not surprisingly, the actual dose intensities ofthe indi-
vidual drugs (except for vincristine) were significantly higher with
the rhG-CSF regimen. Accordingly, the mean total received dose
intensity for all drugs was significantly higher in the rhG-CSF
group (84% of the projected dose for rhG-CSF patients vs 72%
in the controls, P = 0.03). The use of rhG-CSF thus allowed an
increase in the intensity ofthe delivered dose.
Table 3 shows the results achieved using CODE chemotherapy.
The median response durations for the rhG-CSF and the control
groups were 33 and 22 weeks respectively (Figure 1). The differ-
ence was ofborder line significance (P = 0.0546).
Median follow-up of living patients was 42.3 months. At the
time of this analysis 24 patients in the rhG-CSF group and 21 in
the control group had died because ofdisease (Table 3). Two in the
rhG-CSF group and five in the control group died because of
causes unrelated to this disease. The 45-week median survival
time for all patients is superior to that reported in the literature
(Aisner et al, 1983). The median survival time in the rhG-CSF
group was 59 weeks (95% confidence interval, CI, 45.6-90.9)
compared with 32 weeks in the control group (95% CI, 24.4-41.4;
P = 0.004) (Figure 2). The 1-, 2- and 3-year actuarial survival rates
in patients treated with rhG-CSF were 59.4%, 31.3% and 9.4%
compared with 22.6%, 6.5% and 3.2%, respectively, in the patients
treated without rhG-CSF.
Univariate analysis ofprognostic factors showed that treatment
with rhG-CSF alone seemed to be associated with a statistically
significant prognostic value (P = 0.0040). Liver metastases (P =
0.0510) and serum CEA level (P = 0.0573) had a marginal effect.
Sex, age, performance status, lactate dehydrogenase level and
brain metastasis were not predictive of survival. Multivariate
analysis according toprognostic factors clearly confirms that treat-
ment with rhG-CSF is the only variable that significantly affects
patient survival (Table 4).
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Figure 2 Survival in patients with extensive-stage small-cell lung cancer. The
median survival times were 59 weeks in the rhG-CSF group (-) and 32
weeks in the control group (----) respectively (P = 0.0004). The 1-, 2- and 3-
year survival rates in the rhG-CSF group were 59.4%, 31.3% and 9.4%
compared with 22.6%, 6.5% and 3.2% respectively, in the control group
DISCUSSION
This trial clearly demonstrated that the use of rhG-CSF in the
CODE regimen was associated with an increase in delivered dose
intensity (Table 2). At the same time, the CODE plus rhG-CSF
regimen was associated with a 27-week prolongation of median
survival and an about fivefold increase in the 2-year survival rate
(31.3% vs 6.5%) compared with the CODE-only group. The
median survival time of 32 weeks in patients who received CODE
alone is similar to that reported for extensive-stage patients (Aisner
et al, 1983). Therefore, this is the first randomized study in SCLC
patients receiving rhG-CSF with chemotherapy to show that the
administration of rhG-CSF results in significant prolongation of
survival through the increase in cytotoxic dose-intensity. The
results obtained here contrast sharply with those reported by Miles
et al (1994). In their randomized trial of weekly chemotherapy of
cisplatin and etoposide alternating with ifosfamide and doxorubicin
with or without rhG-CSF in SCLC, the proportion ofpatients expe-
riencing dose reductions as the result of leukopenia was signifi-
cantly higher in the control arm than in the rhG-CSF arm (P <
0.04). However, cycle delays because ofleukopenia were similar in
both arms. Furthermore, non-haematological toxicities, such as
increased creatinine concentration, also prevented an increase in
the received dose intensity. Therefore, administration of rhG-CSF
did not allow a significant increase in the received dose intensity
(84% in the rhG-CSF arm vs 82% in the control). The authors
stated that the use of rhG-CSF may not be suitable for regimens in
which myelosuppressive drugs are administered every week. Their
approach is different from the one used in our trial. As the CODE
regimen was designed by Murray et al (1991 a, b) to give alter-
nating weekly cycles of myelosuppressive and non-myelosuppres-
sive drugs, it may be possible to use rhG-CSF to alleviate
chemotherapy-induced neutropenia. Another trial to test the contri-
bution of rhG-CSF to increasing cytotoxic dose intensity in SCLC
was reported by Woll et al (1995), in which patients were random-
ized to receive vincristine, ifosfamide, carboplatin and etoposide
alone or with rhG-CSF. The rhG-CSF group received a signifi-
cantly higher dose-intensity than the control. The increase in
dose-intensity in the rhG-CSF group was associated with a better
2-year survival rate (32% vs 15%), although the difference in
median survival time (69 weeks vs 65 weeks) was not statistically
significant.
In conclusion, our results clearly demonstrate that, in patients
with extensive-stage SCLC, CODE therapy with rhG-CSF
prolongs the response duration and survival compared with CODE
alone. Data obtained here with the use of rhG-CSF showing a 27-
week improvement in median survival and a major increase in the
2-year survival rate (31.3% vs 6.5%) are very encouraging.
However, most patients with this disease still die within 3 years;
further improvements in systemic therapy are imperative.
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